DESTINY-Breast09 delivered progression-free survival approaching four years with T-DXd plus pertuzumab—a result that reshapes expectations for first-line HER2-positive metastatic disease. This clip breaks down why these results are both statistically and clinically meaningful.
DESTINY-Breast09: Nearly 4 Years of PFS with T-DXd
You may also like
Recommended Videos
